Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Sunday, November 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Complement-Based Drug Development Summit leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Sreoshi Chatterjee
  • Page 15

Author

Sreoshi Chatterjee 452 posts 0 comments

Alfa Scientific Designs assert FDA 510(k) clearance for Driven Flow Technology

Feb 26, 2018
Alfa Scientific Designs, the US manufacturer of rapid, point-of care medical devices asserted that the FDA has extended the 510(k) clearance for  ALFA's iFOB with Driven Flow…
Read More...

MabSpace Biosciences declares FDA approval of IND for MSB2311

Feb 26, 2018
MabSpace Biosciences declares FDA cleared investigational New Drug for MSB2311 which is a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with…
Read More...

FDA clearance received for Endomag’s Magseed Marker

Feb 26, 2018
Surgical guidance company, Endomag asserted that it has sought 510 (k) clearance from the US Food and Drug Administration to further extend the indication of its Magseed magnetic marker…
Read More...

Kadmon declares updated optimistic results of Phase 2 study of KD025-208 in cGVHD

Feb 26, 2018
Kadmon Holdings claimed positive results from ongoing Phase 2 Clinical trial KD025-208 assessing updated optimistic results from an ongoing Phase 2 Clinical Trial KD025-208 evaluating…
Read More...

Puma Biotechnology asserts CHMP’s negative opinion on MAA for Neratinib

Feb 26, 2018
Puma Biotechnology asserted that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion thereby refuting to grant Marketing…
Read More...

Pfizer declares update on EMAP for SUTENT in RCC patients

Feb 26, 2018
Pfizer asserted that the Committee for Medicinal Products for human use of the European Medicines Agency has disapproved of expanding use of SUTENT to encompass the adjuvant treatment…
Read More...

CEL-SCI extends the Expiration Date of Series DD and Series EE Warrants issued

Feb 26, 2018
CEL-SCI Corporation asserted that it was extending the expiration date of its Series DD and Series EE warrants to July 1, 2018. The Series DD and Series EE warrants were issued on…
Read More...

PacBridge Capital Partners (HK) acquires Contextual Genomics

Feb 26, 2018
Hong Kong based investment firm, PacBridge Capital Partners has committed to invest C$12,000,000 in Contextual Genomics, leading Canadian Cancer genomics company headquartered in…
Read More...

Pfizer sought CHMP Opinion for MYLOTARG and BOSULIF

Feb 26, 2018
Pfizer asserted that that the Committee for Medicinal products for Human use of the European Medicines Agency has adopted positive opinions extending marketing authorizations in the EU…
Read More...

AstraZeneca asserts the availability of FLUMIST QUADRIVALENT Vaccine in U.S

Feb 22, 2018
AstraZeneca asserted that the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the…
Read More...
Prev Next
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
8th RNAi-Based Therapeutics Summit
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
RNA-Targeted Drug Discovery & Development Summit
RNA-Based Therapeutics & Vaccines Summit South Korea
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Adalvo Acquires Enzene’s Romiplostim Biosimilar Programme
  • Appian and PSI CRO Partner to Bring AI Into Clinical Trials
  • Pfizer Partners With Edison Scientific to Accelerate AI-Driven Drug Research
  • Dren Bio Raises $350M to Advance Experimental Blood Cancer Drug
  • Glenmark Opens Major US Pharmaceutical Distribution Center in Pennsylvania

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.